NASDAQ:DARE Daré Bioscience (DARE) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free DARE Stock Alerts $0.29 -0.01 (-3.38%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.28▼$0.2950-Day Range$0.28▼$0.5752-Week Range$0.27▼$1.10Volume415,941 shsAverage Volume434,909 shsMarket Capitalization$28.77 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Daré Bioscience alerts: Email Address Daré Bioscience MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside1,997.9% Upside$6.00 Price TargetShort InterestHealthy0.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.07Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.22) to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.82 out of 5 starsMedical Sector595th out of 909 stocksBiotechnology Industry5th out of 15 stocks 3.2 Analyst's Opinion Consensus RatingDaré Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageDaré Bioscience has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.23% of the outstanding shares of Daré Bioscience have been sold short.Short Interest Ratio / Days to CoverDaré Bioscience has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daré Bioscience has recently decreased by 48.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDaré Bioscience does not currently pay a dividend.Dividend GrowthDaré Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DARE. Previous Next 1.6 News and Social Media Coverage News SentimentDaré Bioscience has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Daré Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for DARE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Daré Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Daré Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Daré Bioscience is held by insiders.Percentage Held by InstitutionsOnly 6.70% of the stock of Daré Bioscience is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Daré Bioscience are expected to grow in the coming year, from ($0.22) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Daré Bioscience is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Daré Bioscience is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Daré Bioscience Stock (NASDAQ:DARE)Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Read More DARE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DARE Stock News HeadlinesApril 23, 2024 | globenewswire.comDaré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1April 19, 2024 | msn.comBrookline Capital Downgrades Daré Bioscience (DARE)April 24, 2024 | Wealthpin Pro (Ad)One trade. One ticker. One week. Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? April 19, 2024 | americanbankingnews.comBrookline Capital Management Downgrades Daré Bioscience (NASDAQ:DARE) to HoldApril 11, 2024 | globenewswire.comDaré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal ContraceptiveApril 5, 2024 | yahoo.comNickelodeon 'Double Dare' host Marc Summers says 'Quiet on Set' producers blindsided himApril 5, 2024 | yahoo.comDare to dream: How Fort Worth woman brings hope to ‘communities of underprivileged’April 4, 2024 | yahoo.comThe DARE Program Tried to Reshape the Image of Police Officers in the United StatesApril 24, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: BiomX (PHGE), Daré Bioscience (DARE)April 3, 2024 | yahoo.comKelly Clarkson Sings 'I Dare You' (Appelle Ton Amour) | KellyokeApril 1, 2024 | finance.yahoo.comDaré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 Dare Bioscience Inc Earnings CallMarch 29, 2024 | msn.comKogi Assembly confirms 11 new appointees of Gov OdodoMarch 28, 2024 | finanznachrichten.deDaré Bioscience, Inc.: Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateMarch 28, 2024 | globenewswire.comDaré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateMarch 27, 2024 | msn.comVampire Survival Game V Rising to Get Castlevania CrossoverMarch 21, 2024 | globenewswire.comDaré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024March 18, 2024 | msn.comWomen’s Health Niche Holds $350 Billion Market OpportunityMarch 14, 2024 | barrons.comMadrigal Pharmaceuticals Inc.March 14, 2024 | yahoo.comDare Me Season 1 Streaming: Watch & Stream Online via NetflixMarch 6, 2024 | yahoo.comDare County Schools dismissing early due to rain, flooding forecastMarch 6, 2024 | yahoo.comDare County Schools announce early dismissal due to weatherFebruary 27, 2024 | time.comThe Press: $1,000 DareFebruary 22, 2024 | finance.yahoo.comDaré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual MeetingFebruary 20, 2024 | msn.comWatch Grammy winner Tyla's latest music video for 'Truth Or Dare'February 13, 2024 | msn.comRemote learning day for Dare CountySee More Headlines Receive DARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DARE CUSIPN/A CIK1401914 Webwww.darebioscience.com Phone(858) 926-7655Fax617-494-1544Employees23Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+2,011.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,160,000.00 Net MarginsN/A Pretax Margin-1,074.11% Return on Equity-1,482.38% Return on Assets-120.75% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.86 Sales & Book Value Annual Sales$2.81 million Price / Sales10.18 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-5.68Miscellaneous Outstanding Shares100,582,000Free Float95,251,000Market Cap$28.58 million OptionableNot Optionable Beta1.16 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMs. Sabrina Martucci Johnson (Age 57)CEO, President, Principal Financial Officer, Secretary & Director Comp: $804.07kMs. Lisa Walters-Hoffert (Age 65)Executive Officer Comp: $523.2kMr. Mark Walters (Age 69)Vice President of Operations Ms. MarDee J. Haring-Layton (Age 48)Chief Accounting Officer Dr. David FriendChief Scientific OfficerKey CompetitorsNRx PharmaceuticalsNASDAQ:NRXPAprea TherapeuticsNASDAQ:APRELexaria BioscienceNASDAQ:LEXXSpruce BiosciencesNASDAQ:SPRBImmunoPrecise AntibodiesNASDAQ:IPAView All Competitors DARE Stock Analysis - Frequently Asked Questions Should I buy or sell Daré Bioscience stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DARE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DARE, but not buy additional shares or sell existing shares. View DARE analyst ratings or view top-rated stocks. What is Daré Bioscience's stock price target for 2024? 3 equities research analysts have issued 12 month price objectives for Daré Bioscience's shares. Their DARE share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,997.9% from the stock's current price. View analysts price targets for DARE or view top-rated stocks among Wall Street analysts. How have DARE shares performed in 2024? Daré Bioscience's stock was trading at $0.3090 at the beginning of the year. Since then, DARE stock has decreased by 7.4% and is now trading at $0.2860. View the best growth stocks for 2024 here. Are investors shorting Daré Bioscience? Daré Bioscience saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 235,000 shares, a decrease of 48.5% from the March 15th total of 456,200 shares. Based on an average daily volume of 385,200 shares, the days-to-cover ratio is currently 0.6 days. View Daré Bioscience's Short Interest. When is Daré Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our DARE earnings forecast. How were Daré Bioscience's earnings last quarter? Daré Bioscience, Inc. (NASDAQ:DARE) issued its earnings results on Thursday, March, 28th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.06. The biotechnology company earned $1.81 million during the quarter, compared to analysts' expectations of $2.17 million. What other stocks do shareholders of Daré Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE). How do I buy shares of Daré Bioscience? Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DARE) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
